Quinn T Ostrom1, Halle L Krebs2, Nirav Patil3, Gino Cioffi4,5, Jill S Barnholtz-Sloan6,7,8,9,10. 1. Department of Medicine, Section of Epidemiology and Population Sciences, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. 2. The Ohio State University, Columbus, OH, USA. 3. Research Health Analytics and Informatics, University Hospitals Health System (UHHS), Cleveland, OH, USA. 4. Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, 2-526 Wolstein Research Building, 2103 Cornell Road, Cleveland, OH, 44106-7295, USA. 5. Cleveland Center for Health Outcomes Research (CCHOR), Cleveland, OH, USA. 6. Research Health Analytics and Informatics, University Hospitals Health System (UHHS), Cleveland, OH, USA. jsb42@case.edu. 7. Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, 2-526 Wolstein Research Building, 2103 Cornell Road, Cleveland, OH, 44106-7295, USA. jsb42@case.edu. 8. Cleveland Center for Health Outcomes Research (CCHOR), Cleveland, OH, USA. jsb42@case.edu. 9. Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA. jsb42@case.edu. 10. Cleveland Institute for Computational Biology, Cleveland, OH, USA. jsb42@case.edu.
Abstract
PURPOSE: Race/ethnicity have been previously shown to significantly affect survival after diagnosis with glioblastoma, but the cause of this survival difference is not known. The aim of this study was to examine variation in treatment pattern and time to treatment by race/ethnicity, and the extent to which this affects survival. METHODS: Data were obtained from the National Cancer Database (NCDB) for adults ≥ 40 with glioblastoma from 2004 to 2016 (N = 68,979). Treatment patterns and time to treatment by race/ethnicity were compared using univariable and multivariable logistic and linear regression models, respectively, and adjusted for known prognostic factors and factors potentially affecting health care access. RESULTS: Black non-Hispanics (BNH) and Hispanics were less likely to receive radiation and less likely to receive chemotherapy as compared to White non-Hispanics (WNH). Time to radiation initiation was ~ 2 days longer and time to chemotherapy initiation was ~ 4 days longer in both groups in comparison to WNH. CONCLUSION: Both race/ethnicity and treatment timing significantly affected survival time, and this association remained after adjustment for known prognostic factors. Additional research is necessary to disentangle the specific causal factors, and the mechanism with which they affect survival.
PURPOSE: Race/ethnicity have been previously shown to significantly affect survival after diagnosis with glioblastoma, but the cause of this survival difference is not known. The aim of this study was to examine variation in treatment pattern and time to treatment by race/ethnicity, and the extent to which this affects survival. METHODS: Data were obtained from the National Cancer Database (NCDB) for adults ≥ 40 with glioblastoma from 2004 to 2016 (N = 68,979). Treatment patterns and time to treatment by race/ethnicity were compared using univariable and multivariable logistic and linear regression models, respectively, and adjusted for known prognostic factors and factors potentially affecting health care access. RESULTS: Black non-Hispanics (BNH) and Hispanics were less likely to receive radiation and less likely to receive chemotherapy as compared to White non-Hispanics (WNH). Time to radiation initiation was ~ 2 days longer and time to chemotherapy initiation was ~ 4 days longer in both groups in comparison to WNH. CONCLUSION: Both race/ethnicity and treatment timing significantly affected survival time, and this association remained after adjustment for known prognostic factors. Additional research is necessary to disentangle the specific causal factors, and the mechanism with which they affect survival.
Entities:
Keywords:
Ethnicity; Glioma; National cancer database; Race; Survival; Treatment timing
Authors: Jacob J Mandel; Michael Youssef; Jooyeon Nam; Akash J Patel; Ali Jalali; Ethan B Ludmir; Diane Liu; Jimin Wu; Georgina Armstrong; Jason Huse; Melissa Bondy; John F de Groot Journal: J Neurooncol Date: 2019-01-22 Impact factor: 4.130
Authors: Emily V Dressler; Meng Liu; Catherine R Garcia; Therese A Dolecek; Thomas Pittman; Bin Huang; John L Villano Journal: Neurooncol Pract Date: 2018-05-22
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Alan Hauser; Sunil W Dutta; Timothy N Showalter; Jason P Sheehan; Surbhi Grover; Daniel M Trifiletti Journal: J Clin Neurosci Date: 2017-11-04 Impact factor: 1.961
Authors: Victor M Lu; Ashish H Shah; Daniel G Eichberg; Alfredo Quinones-Hinojosa; Yoshua Esquenazi; Ricardo J Komotar; Michael E Ivan Journal: J Neurooncol Date: 2020-03-31 Impact factor: 4.130
Authors: Krissia M Rivera Perla; Oliver Y Tang; Shayla N M Durfey; Tito Vivas-Buitrago; Wendy J Sherman; Ian Parney; Joon H Uhm; Alyx B Porter; Heinrich Elinzano; Steven A Toms; Alfredo Quiñones-Hinojosa Journal: J Neurooncol Date: 2022-05-03 Impact factor: 4.130
Authors: Leticia M Nogueira; Helmneh M Sineshaw; Ahmedin Jemal; Craig E Pollack; Jason A Efstathiou; K Robin Yabroff Journal: JAMA Netw Open Date: 2022-04-01